2018 was also a very good year in the fight against Prostate Cancer in general: A couple of major (multicenter) studies (4M – Euro. Uro., PRECISION – N. Eng J Med, MRI-first - Lancet and Costa et al. Eur. Uro.) have shown that we can reduce the amount of biopsies in men by 27- 49% in using MRI diagnostics followed by targeted biopsies. Less insignificant cancers are found which will result in less unnecessary treatment of men. While up to 12% more (small) significant cancers can be detected. We are looking forward what 2019 will bring!
Soteria Medical is working on many exciting product developments in the field of MR-guided interventions with a focus on prostate cancer diagnosis and treatment. We expect to release the next products in 2019, while continuing to work with our clinical and industrial partners across the globe.
We are looking forward to another very busy and successful year in 2019.